Thelansis’s “Systemic Amyloidosis Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Systemic amyloidosis is a rare, progressive disorder in which misfolded amyloid fibrils accumulate extracellularly across multiple organs—including the heart, kidneys, liver, gastrointestinal tract, and nervous system—causing progressive dysfunction and significant morbidity. The predominant subtype, AL (light‑chain) amyloidosis, results from plasma cell dyscrasias producing monoclonal immunoglobulin light chains; AA amyloidosis arises secondary to chronic inflammatory conditions; and hereditary variants such as ATTR amyloidosis stem from mutations in transthyretin or other precursor proteins. Diagnosis relies on tissue biopsy with Congo red staining, which reveals apple‑green birefringence under polarized light, followed by precise amyloid typing using immunohistochemistry, mass spectrometry, or genetic testing. Prognostic assessment is guided by staging systems that integrate cardiac biomarkers and renal parameters. Treatment is subtype‑specific: AL amyloidosis is managed with plasma cell‑directed therapies including bortezomib‑based regimens, immunomodulatory drugs, autologous stem cell transplantation, and novel agents such as daratumumab; ATTR amyloidosis is treated with transthyretin stabilizers (tafamidis) or gene‑silencing therapies (patisiran, inotersen); and AA amyloidosis requires control of the underlying inflammatory disease. Despite advances, prognosis remains variable, with cardiac involvement in AL amyloidosis conferring poor outcomes, though modern therapies are improving survival and quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Systemic Amyloidosis – Market Access and Reimbursement Insights Report – 2025 report
Our team will get in touch with you shortly about the Systemic Amyloidosis – Market Access and Reimbursement Insights Report – 2025 report.